SCHEMBL29375415

SCHEMBL29375415

COc1ccc2c(Br)cccc2n1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.55
GRM5 P41594 2/20 0.43
KCNH2 Q12809 2/20 0.43
KDM4E B2RXH2 2/20 0.42
HPGD P15428 2/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.41
EGFR P00533 1/20 0.39
NQO2 P16083 5/20 0.39
CYP1A2 P05177 1/20 0.39
KMT2A Q03164 1/20 0.39
BCL2L11 O43521 1/20 0.38
BCL2L1 Q07817 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2191375 1.00 BACE1 (0.55) BACE1GRM5KCNH2KDM4EHPGD
SCHEMBL16705377 0.79 POLB (0.47) GRM5KCNH2KDM4EHPGDALDH1A1
SCHEMBL827877 0.79 LMNA (0.49) BACE1KDM4EHPGDALDH1A1POLB
SCHEMBL28415013 0.78 BACE1 (0.64) BACE1GRM5KCNH2KDM4EHPGD
SCHEMBL9184397 0.78 KDM4E (0.42) GRM5KCNH2KDM4EHPGDALDH1A1
SCHEMBL31179390 0.78 HTR3A (0.46) BACE1KDM4EHPGDALDH1A1POLB
SCHEMBL16008615 0.78 POLB (0.50) KDM4EHPGDALDH1A1POLBNQO2
SCHEMBL3532637 0.78 HTR3A (0.46) BACE1KDM4EHPGDALDH1A1POLB
SCHEMBL30719617 0.78 POLB (0.50) KDM4EHPGDALDH1A1POLBNQO2
SCHEMBL23619770 0.76 NQO2 (0.42) KDM4EHPGDALDH1A1EGFRNQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2025-09-25 US disclosed
US-12202816-B2 Compounds as NADPH oxidase inhibitors CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2025-01-21 US disclosed
US-20220033379-A1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2022-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP BACE1 2777/4885GRM5 3329/4885KCNH2 4808/4885
US-12202816-B2 Compounds as NADPH oxidase inhibitors CYBB, NOX1, NOX4 BACE1 1638/4885GRM5 2656/4885KCNH2 4184/4885
US-20220033379-A1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS CYBB, NOX1, NOX4 BACE1 1720/4885GRM5 2772/4885KCNH2 4048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.